関連する実験動画
Updated: Sep 9, 2025
08:15
Gastrointestinal Motility Monitor GIMM
Published on: December 1, 2010
31.0K
ピエゾノックダウンは,エンテロクロマフィン細胞からの5 - ヒドロキシトリプタミンの放出を減らし,機能性便秘のマウスの腸内不運動を悪化させる
Xiangyun Yan1, Peitao Ma1, Wen Wang1
1School of Acupuncture and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, P.R. China.
International journal of molecular medicine
|September 5, 2025
まとめ
機能性便秘では,腸の健康とセロトニン分泌の維持にピエゾ1とピエゾ2の経路が不可欠です. エントロクロマフィン細胞におけるそれらの結合作用は,腸の正常な機能に不可欠である.
科学分野:
- 胃腸内科
- 分子生物学
- 細胞生理学
背景:
- エントロクロマフィン (EC) 細胞機能障害と5-ヒドロキシトリプタミン (5-HT) の分泌量の低下は,機能性便秘 (FC) に関わっている.
- 特にイオンチャネルを伴うEC細胞機能とFC病原性を結びつける正確なメカニズムは,ほとんど不明である.
- ピエゾイオンチャネルは,EC細胞からの5-HT放出を調節することが知られている.
研究 の 目的:
- 機能性便秘の病原性におけるPiezo1とPiezo2の役割と根本的なメカニズムを調査する.
- 皮エゾ1とピエゾ2がEC細胞機能と腸内ホメオスタシスを調節する相互作用を調査する.
- FCモデルにおける5-HTシグナル伝達と胃腸運動に対するピエゾチャネル機能障害の影響を評価する.
主な方法:
- ロペラミド誘発機能性便秘のマウスモデルを使用した.
- マウスにおけるPiezo1とPiezo2の in vivo ノックダウンのためにアデノ関連ウイルスを使用した.
- QGP-1細胞系 (EC型細胞) でレンチウイルス媒介によるノックダウンを用いたin vitro試験を実施した.
- 腸の運動,胃腸の通過,胃の排泄,小腸の推進を評価した.
- 5-HT,5-HT3受容体,トリプトファンヒドロキシラーゼ-1 (TPH-1),物質P,セロトニントランスポーター,ERK,PKCリン酸化を測定した.
主要な成果:
- FCマウスでは,Piezo1とPiezo2のEC細胞との発現とコロカライゼーションの減少が観察された.
- Piezo1またはPiezo2のノックダウンにより腸の運動能力が低下し,経路が遅れて,胃の排泄が遅れて,推進力が低下した.
- 5HT,5-HT3受容体,およびTPH-1のレベルは,ピエゾチャネルノックダウン後に減少した.
- ダブル・ノックダウンはFCの症状を悪化させ,大腸の異常と神経伝達物質/伝達物質のレベルを変化させた.
- ピエゾチャネルノックダウンにより,ERKとPKCのリン酸化が抑制され,二重ノックダウンによりPKCに顕著な効果が示された.
- 細胞内カルシウム,5-HT,TPH-1の有意な低下を導いた.
結論:
- ピエゾ1とピエゾ2は,機能性便秘における腸内ホメオスタシスの維持に重要な役割を果たします.
- これらのチャネルは共同でEC細胞のカルシウムイオン流入を調節し,それによって5-HTシグナル伝達を調整する.
- 機能性便秘の管理のための新たな治療戦略を提示しています.
関連する概念動画
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
395
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
395
01:21Drugs for Treatment of Constipation-Predominant IBS
322
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
322
01:17Drugs for Treatment of Diarrhea-Predominant IBS
289
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
289
01:20Drugs Affecting GI Tract Motility: Other Laxatives
443
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
443
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
591
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
591
01:22Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
303
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
303